Skip to main content
. 2019 Apr 3;10:269. doi: 10.3389/fphar.2019.00269

Figure 5.

Figure 5

Ac2-26 reduces cardiac inflammation 48 h post I-R injury in vivo. Representative immunofluorescent images of (A) LV inflammatory cell content (determined using anti-Ly-6B.2 antibody, (C) LV macrophage content (determined using anti-CD68 antibody, E) LV neutrophil content (determined using anti-Ly6G+ antibody) from sham, vehicle- and Ac2-26-(1 mg/kg/day, i.v.)-treated mice, 48 h post I-R (X400 magnification, scale-bar in top panels = 100 μm; in bottom panels = 50 μm). Pooled data for (B) LV Ly6B.2 positive, (D) C68+ positive, and (F) Ly6G+ positive immunofluorescence. Higher magnification images reveals overlay of dark blue (DAPI; detecting nuclei) and red (inflammatory cells) indicating positive staining (scale-bar in top panels = 100 μm; in bottom panels = 50 μm). #P < 0.05, ##P < 0.01, ####P < 0.0001 versus sham, ∗P < 0.05 versus vehicle-treated mice. One-way ANOVA with Tukey’s post hoc test. Data were presented as mean ± SEM, with number of mice per group. n = 6 (sham), n = 7 (I-R + vehicle), and n = 8 (I-R + Ac2-26).